The decline in skeletal muscle mass and strength occurring in aging, referred as sar‐copenia, is the result of many factors including an imbalance between protein synthe‐sis and degradation, changes in metabolic/hormonal status, and in circulating levels of inflammatory mediators. Thus, factors that increase muscle mass and promote anabolic pathways might be of therapeutic benefit to counteract sarcopenia. Among these, the insulin‐like growth factor‐1 (IGF‐1) has been implicated in many anabolic pathways in skeletal muscle. IGF‐1 exists in different isoforms that might exert differ‐ent role in skeletal muscle. Here we study the effects of two full propeptides IGF‐1Ea and IGF‐1Eb in skeletal muscle, with the aim to define whether and through which mechanisms their overexpression impacts muscle aging. We report that only IGF‐1Ea expression promotes a pronounced hypertrophic phenotype in young mice, which is maintained in aged mice. Nevertheless, examination of aged transgenic mice revealed that the local expression of either IGF‐1Ea or IGF‐1Eb transgenes was protective against age‐related loss of muscle mass and force. At molecular level, both isoforms activate the autophagy/lysosome system, normally altered during aging, and increase P GC1‐α expression, modulating mitochondrial function, ROS detoxification, and the basal inflammatory state occurring at old age. Moreover, morphological integrity of neuromuscular junctions was maintained and preserved in both MLC/IGF‐1Ea and MLC/IGF‐1Eb mice during aging. These data suggest that IGF‐1 is a promising thera‐peutic agent in staving off advancing muscle weakness.

Ascenzi, F., Barberi, L., Dobrowolny, G., Villa Nova Bacurau, A., Nicoletti, C., Rizzuto, E., Rosenthal, N., Scicchitano, B. M., Musarò, A., Effects of IGF‐1 isoforms on muscle growth and sarcopenia, <<AGING CELL>>, 2019; 2019 (april): 1-11. [doi:10.1111/acel.12954] [http://hdl.handle.net/10807/133905]

Effects of IGF‐1 isoforms on muscle growth and sarcopenia

Scicchitano, Bianca Maria
Penultimo
;
2019

Abstract

The decline in skeletal muscle mass and strength occurring in aging, referred as sar‐copenia, is the result of many factors including an imbalance between protein synthe‐sis and degradation, changes in metabolic/hormonal status, and in circulating levels of inflammatory mediators. Thus, factors that increase muscle mass and promote anabolic pathways might be of therapeutic benefit to counteract sarcopenia. Among these, the insulin‐like growth factor‐1 (IGF‐1) has been implicated in many anabolic pathways in skeletal muscle. IGF‐1 exists in different isoforms that might exert differ‐ent role in skeletal muscle. Here we study the effects of two full propeptides IGF‐1Ea and IGF‐1Eb in skeletal muscle, with the aim to define whether and through which mechanisms their overexpression impacts muscle aging. We report that only IGF‐1Ea expression promotes a pronounced hypertrophic phenotype in young mice, which is maintained in aged mice. Nevertheless, examination of aged transgenic mice revealed that the local expression of either IGF‐1Ea or IGF‐1Eb transgenes was protective against age‐related loss of muscle mass and force. At molecular level, both isoforms activate the autophagy/lysosome system, normally altered during aging, and increase P GC1‐α expression, modulating mitochondrial function, ROS detoxification, and the basal inflammatory state occurring at old age. Moreover, morphological integrity of neuromuscular junctions was maintained and preserved in both MLC/IGF‐1Ea and MLC/IGF‐1Eb mice during aging. These data suggest that IGF‐1 is a promising thera‐peutic agent in staving off advancing muscle weakness.
2019
Inglese
Ascenzi, F., Barberi, L., Dobrowolny, G., Villa Nova Bacurau, A., Nicoletti, C., Rizzuto, E., Rosenthal, N., Scicchitano, B. M., Musarò, A., Effects of IGF‐1 isoforms on muscle growth and sarcopenia, <<AGING CELL>>, 2019; 2019 (april): 1-11. [doi:10.1111/acel.12954] [http://hdl.handle.net/10807/133905]
File in questo prodotto:
File Dimensione Formato  
Ascenzi_et_al-2019-Aging_Cell.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/133905
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 143
  • ???jsp.display-item.citation.isi??? 143
social impact